effect of anticoagulants on plasma HAase activity was evaluated and compared with the serum HAase activity that is devoid of anticoagulants as no study provides information in this regard. The results suggested that the plasma HAase activity in the presence of the recommended concentration of EDTA was highly comparable/similar to that of the serum HAase activity. In contrast, citrated or heparinized plasma recorded a significantly reduced level of activity than that of the serum HAase activity. In conclusion, our results suggested that the EDTA-treated plasma samples are a better choice compared with heparin and citrated samples to assess the HAase activity. J. Clin. Lab. Anal. Key words: Hyal-1; hyaluronidase; hyaluronan; anticoagulants; plasma; serum Mammalian hyaluronidases (HAases) are an endo-b-Nacetyl-hexosaminidases that degrade hyaluronan (HA). HA is a multifunctional, nonsulfated, high-molecularweight polysaccharide found throughout the animal kingdom, especially in the extracellular matrix of soft connective tissues (1) (2) (3) . The key role of the HA-HAase system has been recognized in a number of pathophysiological processes such as embryogenesis, angiogenesis, inflammation, disease progression, wound healing, microbial infection, and the diffusion of systemic toxins/venoms (3) (4) (5) . Several studies have confirmed that the altered HAase activity was observed in liver cirrhosis, liver fibrosis, diabetes, osteoarthritis, transplantation, and tumor progression (3, 6, 7) . Circulatory HA levels, on the other hand, increase in response to shock, blood loss, septicemia, extensive burn, and following massive trauma or post surgery conditions (3, (8) (9) (10) (11) .
There are six HAase-like sequences in the human genome-hHyal-1 through -4, PH-20, and pseudogene PHYAL1. Hyal-1, Hyal-2, and PH-20 are associated with known HAase enzyme activities (2, 11, 12) . Hyal-1 is the only enzyme present in the circulatory system and is responsible for the catabolism of intracellular and extracellular HA. In contrast, the enzymes involved in the HA synthesis do not circulate freely (2, 13) . Moreover, augmented expressions of Hyal-1 mRNA and elevated levels of hHyal-1 are documented in several diseases (14) (15) (16) (17) .
The inactivating mutations of hHyal-1 are also linked to the human genetic disorder mucopolysaccharidosis IX, which is characterized by periarticular soft tissue masses and augmented plasma HA levels (50-90-folds) than those in normal serum (16) . The assumption is that plasma HAase (hHyal-1) activity may change with thecirculatory HA and its degrading enzyme HAase are considered as diagnostic and prognostic markers for many pathophysiological disease conditions.
In clinical/pathological conditions, such as diabetes, monoclonal gammapathy, and bladder and prostate tumors, analysis of plasma HAase activity has been widely suggested (14) (15) (16) (17) . The preparation of plasma appears to be a critical step as it requires the use of anticoagulants. Citrate, EDTA, and heparin are the commonly used anticoagulants in practice for the plasma preparation. However, the influence of anticoagulants on the level of plasma HAase activity has not been studied. Hence, in this study the effect of anticoagulants on the level of plasma HAase activity has been investigated and compared with the levels of HAase activity in the serum, which is devoid of any anticoagulants.
The plasma samples were prepared independently using standard concentrations (1Â) and also using increasing concentrations (2Â and 3Â) of different anticoagulants such as tri-sodium citrate, di-sodium EDTA, and lithium heparin (Sigma-Aldrich Co., St. Louis, MO). Tri-sodium citrate (1Â: 3.2%, 2Â: 6.4%, and 3Â: 9.6%), di-sodium EDTA (1Â: 2%, 2Â: 4%, and 3Â: 6%), and lithium heparin (1Â: 200 U/ml, 2Â: 400 U/ ml, and 3Â: 600 U/ml) were used. Venous blood samples from healthy individuals (n 5 10) were collected with prior consent and the blood was drawn into plain vacutainer tubes (with no anticoagulants) and the respective anticoagulants were added freshly before the blood samples were dispensed into the tubes (BD Vacutainer Systems, Bedfordshire, UK). The recommended volume of blood (4.5 ml) and 0.5 ml of anticoagulant in each case was mixed well and kept for 15 min at 41C and centrifuged at 1,800 Â g for 15 min to collect the clear plasma. For the preparation of the serum samples, the blood was allowed to clot in the absence of any added anticoagulants and centrifuged for 10 min at 800 Â g to obtain serum.
The quantitative HAase activity was assayed by estimating reduced N-acetyl glucosamine (NAG) new termini generated according to the method of Reissig et al. (18) (Nagaraju et al., communicated to Clinical Biochemistry). The plasma and serum samples (10 ml) were incubated with 290 ml of buffered substrate solution (0.1 M sodium formate, pH 3.8, containing 0.05 M NaCl and 50 mg HA) for 4 hr at 371C. The reaction was terminated by the addition of potassium tetraborate (50 ml, pH 9.1). Adding the p-dimethyl aminobenzaldehyde reagent (stock solution p-DMAB was prepared by dissolving 1 g of p-DMAB in 10 ml of 9:1 mixture of glacial acetic acid and HCl stored at 41C. From this working solution was prepared by diluting it to nine times with glacial acetic acid) resulted in color formation. The absorbance was monitored at 585 nm.
Appropriate negative and positive controls were maintained throughout the experiment. The activity was expressed as mIU. One international unit (IU) corresponds to m moles of NAG released/min/mg protein.
The qualitative HAase activity was determined by the substrate gel zymogram assay (19, 20) . Briefly, HA was incorporated at a final concentration of 0.17 mg/ml into sodium dodecyl sulfate (SDS)-polyacrylamide gel matrix (10%). Each sample was prepared by diluting the plasma and the serum (10 ml diluted to 200 ml) with sample buffer (2% SDS, 125 mM Tris HCl, pH 6.8, 10% glycerol, and 0.001% bromophenol blue). Diluted samples, 10 ml each, were loaded separately and subjected to electrophoresis under nonreduced condition. The gels were then soaked consecutively three times in 50 ml of 0.05 M NaCl in sodium formate buffer (0.1 M, pH 3.8) containing 5, 0.05, and 0% Triton X-100 for 1 hr, followed by equilibrating the gel in 0.1 M sodium formate buffer, pH 3.8, containing 0.05 M NaCl for 16-18 hr at 371C with constant agitation. The gels were stained with Alcian blue (Sigma Chemicals) and then destained with 7% glacial acetic acid. The HAase activity was detected as unstained translucent bands against the background of Alcian blue-stained HA.
The results were statistically evaluated using Student's t-test and one-way analysis of variance. Statistical analyses of the parameters were performed by using the SPSS s statistical program version 11.5 (SPSS Inc., Chicago, IL). A probability value o0.05, o0.01, and o0.001 was considered for the minimum levels of statistical significance.
The quantitative estimation of plasma HAase activity in the presence of different anticoagulants revealed a significantly varied profile of activity. Among the three plasma samples, a prominently low level of HAase activity was observed in both heparinized and citrated plasma, whereas only a marginally low level of activity was seen in EDTA-treated plasma samples compared with the activity seen in serum samples (Fig. 1) . The results clearly indicate that the reduction in the activity appears to be dose dependent and correlates well with the increased doses of heparin used for the preparation of plasma where the progressive decreased activity was seen in 1Â followed by 2Â and 3Â heparinized plasma (Po0.001). Although, 1Â heparinized plasma recorded a significantly reduced HAase activity compared with that of the serum HAase activity, the activity of 2Â and 3Â heparinized plasma was significantly lower compared with that of the activity seen in 1Â (Po0.001). In contrast, although the citrated plasma recorded a much lower HAase activity than that of the activity seen in the serum, the progressive decreased HAase activity was seen only in 1Â and 2Â citrated plasma as there was no further decrease in activity in 3Â plasma (Po0.001).
Thus, above 2Â, citrate will have no influence on HAase activity as 2Â and 3Â plasma recorded a nearly similar activity. Further, the reduced activity of 2Â and 3Â is significant respectively at Po0.001 and Po0.01 compared with that of the activity seen in 1Â plasma samples. On the contrary, EDTA-treated plasma samples exhibited only a marginally decreased HAase activity compared with the serum HAase activity. The 1Â EDTA-treated plasma and the serum HAase activities were nearly similar, whereas 2Â and 3Â plasma showed significantly lower levels of activity compared with the serum (Po0.01) and 1Â plasma (Po0.05) activities (Fig. 1) . It is important to note the fact that unlike heparin, the increasing dose of EDTA (2Â and 3Â) will not have much of a significant impact on the HAase activity (Fig. 2) .
The results of the quantitative estimation of the HAase activity were further substantiated by the qualitative zymogram assay. Figure 3 indicates the activity-banding pattern of plasma samples treated with different anticoagulants. Each anticoagulant-treated plasma sample showed a distinctive activity band exhibiting a differential enzyme activity as evidenced by varied intensity of activity bands depending upon the strength of the anticoagulant used. The intensity of the activity bands is nearly similar in all the EDTA-treated plasma samples, whereas decreased intensity of bands The quantitative HAase activity profiles of serum and plasma samples. The plasma samples were prepared independently using standard concentrations (1Â) and also using increasing concentrations (2Â and 3Â) of different anticoagulants such as tri-sodium citrate (1Â: 3.2%, 2Â: 6.4%, and 3Â: 9.6%), di-sodium EDTA (1Â: 2%, 2Â: 4%, and 3Â: 6%), and lithium heparin (1Â: 200 U/ml, 2Â: 400 U/ml, and 3Â: 600 U/ml). Venous blood samples from healthy individuals (n 5 10) were collected with prior consent and the blood was drawn into plain vacutainer tubes (with no anticoagulants) and the respective anticoagulants were added freshly before the blood samples were dispensed into the tubes. The recommended volume of blood (4.5 ml) and 0.5 ml of anticoagulant in each case was mixed well and kept for 15 min at 41C and centrifuged at 1,800Â g for 15 min to collect the clear plasma. For the preparation of the serum samples, the blood was allowed to clot in the absence of any added anticoagulants and centrifuged for 10 min at 800Â g to obtain the serum. The quantitative HAase activity was assayed according to the method of Reissig et al. (18) (Nagaraju et al., communicated to Clinical Biochemistry). The results were represented both in units (mIU) and optical absorbance (585 nm). A difference in the HAase activity between the serum and plasma samples with increasing concentration of different anticoagulants was considered statistically significant when Po0.05 ( Ã ), Po0.01 ( ÃÃ ), or Po0.001 ( ÃÃÃ ).
Fig. 2.
HAase activities of serum (control) and plasma samples treated with different anticoagulants. The blood samples were then processed to obtain serum and plasma as described in Figure 1 . Further, all samples were assayed for the HAase activity. A difference in the HAase activity between the serum and plasma samples with increasing concentration of different anticoagulants was considered statistically significant when Po0.05 ( Ã ), Po0.01 ( ÃÃ ), or Po0.001 ( ÃÃÃ ).
was observed in both heparin and citrated plasma samples compared with the serum sample. Thus, the inhibitory effect on the plasma HAase activity was observed in heparinized and citrated plasma samples, whereas no significant level of inhibition was observed in the case of EDTA-treated plasma.
The results clearly indicate that the heparin is not an appropriate anticoagulant to estimate the plasma HAase activity. From the literature, inhibition of HAase by heparin has been attributed to a noncompetitive mechanism, suggesting that the binding of heparin is to the site other than the catalytic site of the HAase. This has been confirmed by chemical modification studies using aldehyde dextran (21, 22) . In addition, reports have shown that heparin and heparan sulfate also inhibit human serum and venom HAases (3, 19) . Further, it has been shown that sodium ion is an activator of HAase (23) . The citrate and EDTA both being chelators, it appears that citrate chelates the sodium more strongly ion than EDTA, which shows less affinity for sodium ion whereas more affinity for divalent cations. This could be the plausible mechanism of plasma HAase inhibition by the citrate.
As physicians/clinicians suggest for evaluating particularly the plasma HAase activity during several pathological conditions, such as diabetes, monoclonal gammapathy, and bladder and prostate tumors (14) (15) (16) , prior knowledge of interference by the anticoagulants is very essential. This is in order to avoid misinterpretation of the results obtained. In conclusion, the results of our study positively establish the dose-dependent inhibition of the plasma HAase activity by citrate and heparin with the later showing more inhibition. In contrast, EDTA did not interfere in the assay and hence should be the anticoagulant of choice over citrate and heparin while preparing plasma samples in order to assess the actual level of HAase activity in various clinical/pathological conditions. Activity staining pattern of human serum and plasma HAase. To evaluate the HAase activity in serum (control) and plasma, blood samples from healthy individuals were processed according to the procedure as described earlier. The serum and plasma samples (10 ml) were diluted to 200 ml with nonreducing sample buffer. Thereafter, 10 ml of each sample was loaded in each gel lane and zymogram assay for serum and plasma HAase was performed according to the method as mentioned earlier.
